Matrix Metalloproteinases as Valid Clinical Target

Author(s): Barbara Fingleton

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 3 , 2007

Become EABM
Become Reviewer
Call for Editor


The matrix metalloproteinase family of enzymes has been a pharmaceutical target for over 20 years. In that time, many drugs have been developed but none have successfully passed clinical trials. A significant problem has been development of dose-limiting side-effects that were revealed during long-term clinical trials in diseases such as arthritis and various cancers. There are, however, other clinical settings where evidence for MMP function contributing to the pathophysiology of disease is strong. A number of these settings will be discussed here together with evidence from animal models that MMP inhibition is a valid strategy to be considered. A major advantage with many of these settings is that drug exposure may not have to be long-term and/or systemic thus reducing the possibility that side-effects will stymie MMPI-based therapy.

Keywords: Inflammation, remodeling, acute therapy, topical, cardiovascular disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [333 - 346]
Pages: 14
DOI: 10.2174/138161207779313551
Price: $65

Article Metrics

PDF: 12